PTEN mutation is significantly related to advanced disease, chemotherapy resistance, and poor survival in patients with head and neck cancers, breast, melanoma, colorectal, esophageal, and prostate19,29–34 so that its role as a predictive and prognostic cancer biomarker is increasingly gaining prominence35–37. This evidence concerns the gene PTEN and head and neck cancer.